

Preliminary Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1 (original): A composition comprising the carboxylate form of a camptothecin drug associated with at least one organic cationic molecule having a positive net charge wherein the molar ratio of the organic cationic molecule to the carboxylate and is at least about 1:1 wherein said composition is substantially free of the lactone form of said camptothecin.

Claim 2 (original): The composition of claim 1 wherein said organic cationic molecule is a cationic amphiphile and/or a cationic polymer.

Claim 3 (currently amended): The composition of claim 1 or 2, wherein said cationic amphiphile is selected from lipids, lysolipids or pegylated lipids, preferably having a tertiary amino or quaternary ammonium group such as

N-[1-(2,3-diacyloxy)propyl]-N,N-dimethylamine or
N-[1-(2,3-diacyloxy)propyl]-N,N,N-trimethyl ammonium.

Claim 4 (currently amended): The composition of ~~any one of claims 1 to 3~~ claim 2, wherein said cationic polymer is a polyelectrolyte, acid such as polyallylamine or polyethylene imine, a polymeric sugar or a polyamine with a molecular weight between about 5 and about 500 kDa.

Claim 5 (currently amended): The composition of ~~any one of the claims 1 to 4~~ claim 1, further comprising at least one anionic and/or neutral amphiphile.

Claim 6 (currently amended): The composition of ~~any one of claims 1 to~~ claim 5, wherein said anionic and/or neutral amphiphile is selected from group consisting of sterols or lipids such as

cholesterol, phospholipids, lysolipids, lysophospholipids, sphingolipids or pegylated lipids with a negative or neutral net change.

Claim 7 (currently amended): The composition of ~~any one of the claims 5 to claim 6~~, wherein the neutral amphiphile is diacylphosphatidylcholine.

Claim 8 (currently amended): A colloidal nanoaggregate comprising a composition of ~~any one of the claims 1 to 7~~ claim 1.

Claim 9 (original): The nanoaggregate of claim 8 having an overall positive charge.

Claim 10 (currently amended): The nanoaggregate of claim 8 or 9, further comprising at least one amphiphile which has a negative and/or neutral net charge (anionic and/or neutral amphiphile).

Claim 11 (currently amended): The nanoaggregate of ~~any one of the claims 8 to claim 10~~, wherein said anionic and/or neutral amphiphile is selected from the group consisting of sterols or lipids such as cholesterol, phospholipids, lysolipids, lysophospholipids, sphingolipids or pegylated lipids with a negative or neutral net change.

Claim 12 (currently amended): The nanoaggregate of ~~any one of the claims 8 to claim 11~~, wherein the neutral amphiphile is diacylphosphatidylcholine.

Claim 13 (currently amended): The nanoaggregate of ~~any one of the claims 8 to claim 12~~, comprising an excess of positively charged moieties of at least about 20 %, preferably at least about 30 % and most preferably at least about 40 % in the outer molecular layer.

Claim 14 (currently amended): The nanoaggregate of ~~any one of the claims 8 to claim 13~~, which is present as an emulsion droplet, a micelle, a liposome, a nanoparticle or a nanocapsule.

Claim 15 (currently amended): The nanoaggregate of ~~any one of the claims 8 to claim 14~~, comprising about 0.1 to about 50 mol% of a camptothecin drug or a derivative thereof.

Claim 16 (currently amended): The nanoaggregate of ~~any one of the claims 8 to claim 15~~, further comprising a cryoprotectant which is selected from a sugar or an alcohol or a combination thereof such as trehalose, maltose, sucrose, glucose, lactose, dextran, mannitol or sorbitol.

Claim 17 (currently amended): A pharmaceutical preparation comprising a pharmaceutically effective amount of the composition of ~~any one of the claims 1 to 7 claim 1 or a colloidal nanoaggregate of any one of the claims 8 to 16~~ together with a pharmaceutically acceptable carrier, diluent and/or adjuvant.

Claim 18 (currently amended): A method of producing the colloidal nanoaggregate of ~~any one of the claims 8 to claim 16~~, comprising ~~the steps of:~~:

- a) providing a camptothecin drug, preferably as a salt;
- b) associating said camptotecin drug in its carboxylate form with a cationic amphiphile having a positive net charge and optionally at least one further amphiphile which has a positive, negative and/or neutral net charge; and
- c) forming a colloidal nanoaggregate.

Claim 19 (currently amended): The method of claim 18, wherein steps b) and c) comprise forming said nanoaggregate by a homogenisation, a lipid film or by a solvent injection procedure.

Claim 20 (cancel)

Claim 21 (new): A pharmaceutical preparation comprising a pharmaceutically effective amount of the colloidal nanoaggregate of claim 8 together with a pharmaceutically acceptable carrier, diluent and/or adjuvant.

Claim 22 (new): A method of producing a medicament for treating and/or preventing a disease associated with enhanced angiogenic activity comprising formulating the pharmaceutical composition of claim 17 into the medicament.

Claim 23 (new): A method of producing a medicament for treating and/or preventing a disease associated with enhanced angiogenic activity comprising formulating the pharmaceutical composition of claim 21 into the medicament.